Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
BioNTech (Nasdaq:BNTX) held its 2026 Annual General Meeting, with 92% of share capital represented and all agenda items approved by shareholders.
The Supervisory Board was expanded from six to eight members, adding oncology and commercialization expertise, with Helmut Jeggle elected Chairman and several member mandates extended.
BioNTech (Nasdaq: BNTX) authorized a new ADS repurchase program to buy up to $1.0 billion of American Depositary Shares through May 6, 2027. Repurchases will be funded from existing cash resources and may be executed in open-market transactions, with the company citing capital-allocation discipline and Rule 10b-18/10b5-1 safe-harbor compliance.
BioNTech expects repurchased ADSs to satisfy ordinary-course obligations and says the Program aims to enhance capital efficiency while preserving financial flexibility to support its multi-product objective by 2030.
BioNTech (Nasdaq: BNTX) reported Q1 2026 results: revenues €118.1m, net loss €531.9m (adjusted €494.6m), and cash, cash equivalents and investments €16.8bn. The company initiated five pivotal pumitamig trials, expects six late‑stage readouts in 2026, reaffirmed 2026 revenue guidance of €2.0–2.3bn, announced a $1.0bn ADS buyback program, and plans manufacturing consolidations affecting ~1,860 roles with estimated recurring savings of ~€500m by 2029.
BioNTech (Nasdaq: BNTX) will report first quarter 2026 financial results on May 5, 2026 and host a conference call and webcast at 8:00 a.m. ET / 2:00 p.m. CET.
Investors should register in advance to receive dial‑in numbers and a PIN; slides and audio will be available on the company website and a replay will be archived for 30 days.
BioNTech (Nasdaq: BNTX) reported positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing, recurrent endometrial cancer on April 11, 2026. The cohort (n=145) showed a confirmed ORR of 47.9% in centrally tested patients and mPFS of 8.1 months, with a median DoR of 10.3 months.
The safety profile was manageable; grade ≥3 TRAEs occurred in 46.9% and grade ≥3 ILD/pneumonitis in 4.8%. BioNTech and DualityBio plan a BLA filing in 2026 and an ongoing Phase 3 confirmatory trial is underway.
BioNTech (Nasdaq: BNTX) will present late-stage lung cancer data at ELCC 2026 (March 25-28), highlighting updates on pumitamig, gotistobart and the HER3-targeted ADC BNT326/YL202. Key clinical notes include a reported 54% reduction in risk of death for gotistobart versus chemotherapy in stage 1 PRESERVE-003 and multiple China-based trial updates for pumitamig supporting ongoing global Phase 2/3 and Phase 3 programs.
The portfolio now spans 16 ongoing lung cancer trials, including four pivotal Phase 3 studies and five novel-novel combination trials.
BioNTech (Nasdaq: BNTX) reported full year 2025 revenues of €2.87 billion, an IFRS net loss of €1.14 billion (adjusted net loss €117.1 million) and cash, cash equivalents and investments of €17.24 billion as of December 31, 2025.
The company expects 2026 revenues of €2.0–2.3 billion, adjusted R&D of €2.2–2.5 billion and adjusted SG&A of €700–800 million. Co-founders will form an independent mRNA company with a management transition by end-2026. Multiple late-stage oncology readouts including pumitamig programs are planned for 2026.
BioNTech (Nasdaq: BNTX) announced that co-founders Prof. Ugur Sahin and Prof. Özlem Türeci will form an independent company to develop next-generation mRNA innovations, with BioNTech contributing related rights and technologies for a minority stake and possible milestones/royalties.
A binding agreement is expected by end H1/2026, founders will transition to the new company by end 2026, and BioNTech expects 15 ongoing Phase 3 oncology trials and multiple late-stage readouts in 2026.
BioNTech (Nasdaq: BNTX) will report fourth quarter and full year 2025 financial results on March 10, 2026. A live conference call and webcast for investors and analysts is scheduled for 8:00 a.m. ET (1:00 p.m. CET) that day.
Slides and audio will be available on the company website, with a replay archived for 30 days.
BioNTech (Nasdaq: BNTX) appointed Kylie Jimenez to the Management Board as Chief People Officer, effective March 1, 2026. The newly created role will lead people strategy to support BioNTech’s goal to become a multi-product oncology company by 2030.
Jimenez joins from Georg Fischer with more than 20 years of global HR experience and will be based in Mainz, Germany.